^
Association details:
| Biomarker: | ALK G1202K |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Identification of Novel Alectinib-Resistant ALK Mutation G1202K with Sensitization to Lorlatinib: A Case Report and in silico Structural Modelling
Published date:
03/25/2021
Excerpt:
A 50-year-old Chinese male non-smoker with lung adenocarcinoma...The targeted sequencing consistently identified EML4-ALK gene fusion in both plasma and pleural effusion (PE), as well as a novel ALK G1202K mutation...Lorlatinib was used as the fourth-line therapy, which lead to the considerable efficacy with improved performance status (PS) score and reduced lung metastases.
DOI:
10.2147/OTT.S293901
